The Prolaris test is a multi-gene assay designed to predict the aggressiveness (growth and spread) of prostate cancer. Most of the relevant evidence is on clinical validity, and evidence for the prognostic value of Prolaris is based only on the retrospective analyses of archived material. No studies examined the prospective use of Prolaris on patient outcomes. Two studies examined whether Prolaris results affected clinicians’ treatment decisions. In 1 study, 65% of clinicians changed their treatment recommendation based on Prolaris results. In the second study results caused a change in treatment in 47.8% of patients.
Published May 2016
NICE page: https://www.nice.org.uk/advice/mib65